Background/Aims: The genetics of human height is a frequently studied and complex issue. However, there is limited genetic research of short stature. To uncover the subgroup of patients to have higher yield and to propose a simplified diagnostic algorithm in the next generation era. Methods: This study included 114 Chinese children with height SDS ≤ -2.5 and unknown etiology from 2014 to 2015. Target/whole exome sequencing (referred as NGS) and chromosomal microarray analysis (CMA) were performed on the enrolled patients sequentially to identify potential genetic etiologies. The samples solved by NGS and CMA were retrospectively studied to evaluate the clinical pathway of the patients following a standard diagnostic algorithm. Results: In total, a potential genetic etiology was identified in 41 (36%) patients: 38 by NGS (33.3%), two by CMA (1.8%), and an additional one by both (0.9%). There were 46 different variants in 29 genes and 2 pathogenic CNVs identified. The diagnostic yield was significantly higher in patients with facial dysmorphism or skeletal abnormalities than those without the corresponding phenotype (P=0.006 and P=0.009, respectively, Pearson's χ 2 test). Retrospectively study the cohort indicate 83.3% patients eventually would be evaluated by NGS/CMA. Conclusion: This study confirms the utility of high-throughput molecular detection techniques for the etiological diagnosis of undiagnosed short stature and suggests that NGS could be used as a primary diagnostic strategy. Patients with facial dysmorphism
Introduction
Short stature is defined as a height that is more than 2 standard deviations (SDS) below the corresponding mean for a given age, sex and population [1] . Children with severe short stature have been found to be vulnerable to diverse developmental, social and educational problems [2] . Over one third of the children seen in our pediatric endocrinology clinic are referred for short stature. It is estimated that approximately 80% of height variation within a given population is under genetic control [3] . Genome-wide association studies have identified 697 common variants clustered in 423 loci that together explained 20% of the variation in adult height [4] . In contrast to contributions from common variants in multiple genes on normal height variation, extremes in height are more likely to be caused by rare pathogenic variants in monogenic genes critical for growth control [5] . Wang et al. [6] investigated 1077 genes in 192 children with short stature with no known genetic etiology revealed some cases carrying pathogenic variants in monogenic genes known to cause short stature. However, variant frequency in that cohort were inferred by pooled targeted sequencing. The overall diagnostic yield is difficult to calculate [6] . Other recent studies have shown that 2.5%-10% patients with idiopathic short stature carry disease-causing rare copy number variants (CNVs), indicating that chromosomal microarray analysis (CMA) can also be used as a technique for unexplained short stature [7, 8] . In recent years, endocrinologists realize the importance of genetic evaluation of short stature, especially the pathogenic short stature, as knowing the molecular diagnosis of the disease would help to predict the development of diseases, guide the potential treatment of short stature and future family planning. Studies have proposed several factors that might increase the likelihood for a monogenic cause of short stature based on clinical experiences [9, 10] , such as severe short stature, multiple pituitary hormone deficiency, etc. However, the experiment evidence is lacking.
To examine the genetic causes of short stature, experts have suggested algorithms to diagnose in a stepwise manner. The approach includes various branches, mixed with evaluation of patients' growth-related factors, endocrine system, skeletal anomaly and application of different choices of genetic techniques at different stages of the diagnose and depends on clinicians' experience greatly. Even if the distinct disorders were recognized correctly by clinician, the detect efficiency is low. One reason is the genetic heterogeneity, multiple genes might be involved in one entity, such as Noonan syndrome. Another reason is some of the genes are large in size. It would be both time and labor consuming to investigate by conventional Sanger sequencing. High throughput techniques, like next generation sequencing (NGS) and CMA could detect the variants in genome wide in a single test. And the pricing keep decrease. Thus, the application of such methods in clinical is becoming practical. A guidance of the genetic diagnosis of short stature in this next generation era is in urgent demands.
In this study, we performed NGS and CMA in a cohort of Chinese children with short stature to explore their potential genetic causes. We compared the yields among patients categorized into different phenotypic subgroups and tried to provide meaningful guidance for clinicians to better utilize these high-throughput molecular detection techniques in children with undiagnosed short stature. Furthermore, we retrospectively examined the 114 cases with a standard diagnostic algorithm, and calculated the steps and labors would cost. Finally, we suggested a new algorithm to diagnose short stature in the next generation era. 
Materials and Methods

Cohort
This study was approved by Ethics Committee of Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University (XHEC-C-2017-066). All recruited subjects or their legal guardians provided written informed consent. The cohort was selected from children (age < 18 years) characterized by short stature (height SDS (HtSDS) < -2, compared to age-and sex-matched Chinese population [11] ) who visited or were referred to the pediatric endocrinology clinic from January 2014 to December 2015. Some recognizable causes of short stature had been excluded through prescreening tests: (1) postoperative pituitary tumor; (2) congenital hypothyroidism without treatment; (3) congenital adrenal hyperplasia; (4) hypophosphatemic rickets; (5) Turner syndrome; (6) Down syndrome; (7) achondroplasia caused by FGFR3 G380R variant; (8) Prader-Willi syndrome; (9) mucopolysaccharidosis (MPS), GM1-gangliosidosis, and mucolipidosis type II/ III; (10) glycogen storage disease type I; (11) inherited metabolic disorders associated with short stature; (12) pathogenic CNVs had been identified in some patients with short stature and intellectual disability, and/or multiple congenital anomalies before this study. In total, there were 656 children included in the initial cohort. We further selected individuals with severe short stature (HtSDS ≤ -2.5) with available DNA samples from nuclear family members. Consequently, 114 patients were enrolled in the final cohort (Fig. 1) .
The clinical records of the 114 patients were collected and categorized as follows: age, HtSDS and weight SDS at the first visit/referral or before rhGH treatment. Family history of short stature (HtSDS < -2) or similar phenotypes seen within three generations was considered as positive. Small for gestational age (SGA) was defined as birth weight or/and birth length < -1.88 SDS (i.e. 3rd percentile) relative to gestational age-and sex-matched controls in China. Patients with average DQ/IQ < 70 were diagnosed with developmental delay/intellectual disability (DD/ID). Other congenital anomalies included manifestations presented at birth but not listed separately such as cryptorchidism, hearing loss, cleft lip and palate, and so on. GH provocation tests used arginine and clonidine respectively without sex steroid priming, and the results showed peak serum GH levels < 10 ng/ml were termed as GH deficiency (GHD) and < 5 ng/ml as complete GHD. Insulin like growth factor 1 (IGF1) level lower than age-matched reference was defined as low IGF1 [12] . Patients with GHD and other pituitary hormone deficiency were diagnosed with multiple pituitary hormone deficiency (MPHD). Bone age was assessed from a standard left hand and wrist radiograph and read according to the method of Greulich and Pyle [13] , and bone age was defined as normal if the difference between the bone age and chronological age was within +/-one year. Patients without additional phenotype but having positive family history, abnormal GH and/or IGF1 level, or slight abnormalities on imaging were classified as isolated short stature; patients with only one additional congenital anomaly or abnormal biochemical finding were classified as short stature with one additional phenotype; the rest were classified as short stature with more than one additional phenotype.
DNA extraction
Genomic DNA was extracted from peripheral blood of the enrolled patients, their parents and other available family members using blood genomic DNA extraction kits (Zeesan Biotech, China).
NGS and Validation
For target sequencing and whole exome sequencing (WES), capture library was prepared using ClearSeq Inheried Disease panel and SureSelect All Exon V5 (Agilent) respectively. Among the 114 enrolled patients, 102 underwent target sequencing, 12 underwent WES. The library was sequenced by Illumina HiSeq 4000 to generate 150 bp paired end reads. Data analysis was performed as previously described [14] . In general, the raw data was aligned to the human reference hg19 by BWA. Variants were called following GATK best practice (version 3) from pass filtered reads. The output vcf files were annotated by SNPEff. High frequency variants (with a frequency >1% in 1000 Genomes Project, Exome Aggregation Consortium (ExAC), Exome Variant Server (EVS), or >5% in local exome database with 200 exomes) were removed from the candidate variant list. Variants were subsequently filtered through autosomal recessive and autosomal dominant/de novo inherited pattern. Candidate variants were classified according to recent standards and guidelines from the American College of Medical Genetics and Genomics (ACMG) [15] . Sanger sequencing was applied to confirm and to determine the co-segregation of the underlying causative variants. All primers would be available upon request. 
CMA and Validation
For undiagnosed patient by NGS in this study, CMA was performed using Affymetrix CytoScan HD array as previously described [16] . The pathogenicity of detected CNVs and loss of heterozygocity regions (LOH) were classified based on the ACMG recommendations [17] . In combination of NGS data, if one patient carries a heterozygous pathogentic/likely pathogenic variant in a certain recessive short stature gene, signal of this gene was checked specifically to detect exonic CNVs that might be missed by standard procedure. Quantitative polymerase chain reaction (qPCR) was applied to confirm and to determine the co-segregation of the candidate CNVs. All primers would be available on request.
Statistical analysis
All statistical analyses were performed using SPSS software version13.0. Pearson's χ 2 test (both the total number of valid cases ≥ 40 and all cells had expected count ≥ 5) / Fisher's exact test (the total number of valid cases < 40, more than 1/5 cells had expected count < 5 or 1 cell had expected count < 1) was used to show the differences of diagnostic categories (solved or unsolved) between patients with and those without a certain phenotype, or between patients with different phenotypes. The odds ratio (OR) and 95% confidence interval (95% CI) of different diagnostic categories for the selected factors (family history, SGA, microcephaly, facial dimorphism, skeletal abnormalities, DD/ID, cardiac anomaly, other congenital anomalites, GHD, low IGF1, other biochemical anomalies, abnormal BA and abnormal brain MRI imaging) were also calculated, and forest plots were generated by Stata 12.0 statistical package.
Results
Cohort description
The clinical characteristics of this cohort were summarized in Table 1 Fig. 1A, 1D ). 18 mutant genes are related to autosomal or X-linked dominant disorders. The identified variants all arose de novo, except for the variants carried by P3, P31 and P61 which were maternally inherited. The other affected genes follow an autosomal recessive pattern of inheritance (Supplementary Fig.  1B ). There were two large deletions detected in patient P83 and P75, respectively ( Table  2 , Supplementary Fig. 1E) . A "homozygous" deletion was detected in ERCC8 gene by NGS in P83. However, Sanger sequencing could only find the paternal origin of the variant. We therefore performed qPCR, and confirmed the maternal exon 4 was deleted ( Table  2 , Supplementary Fig. 2A ). Additionally, P75 carries a paternal frameshift variation detected by NGS and a maternal large deletion detected by CMA in exon 3-8 of BLM gene ( Table 2 , Supplementary Fig. 2B ). Four variants were classified with uncertain significance according to recently published ACMG recommendations ( Table 2 , Supplementary  Fig. 1F ). They were recognized to likely cause the diseases, as the patients' phenotype and inheritance patterns were consistent with the corresponding genetic disorders.
Furthermore, based on the recent relevant references [6, [18] [19] [20] and OMIM (https:// www.omim.org/), we found that at least 24 of the detected 29 genes are affected in the recognized growth plate regulatory systems and skeletal development ( Supplementary  Fig. 1C ). To our surprise only two cases (P61, P101) harbour mutations in the GH-IGF1 axis. This suggests the clinicians to shift the focus from classical GH-IGF1 axis to an extended pathway that involve the growth plate and skeletal development.
In addition, two patients (P42 and P109) were diagnosed by CMA. P42 carries one pathogenic loss known to cause Miller-Dieker syndrome and one likely pathogenic gain in 9p24.3 ( Table 2 , Supplementary Fig. 2C ). P109 was validated to have a de novo gain of large size by qPCR (Table 2, Supplementary Fig. 2D ). This 6.7 Mb duplication in 7q31.1q31.31 covers 20 OMIM genes and has not been related to a continuous gene duplication syndrome. However, the mechanism remains obscure.
Diagnostic yield of NGS and CMA 38 of the 114 patients (33.3%) was diagnosed by NGS (Fig. 1) . The genetic findings are listed in Table 2 . Subsequently, three out of 76 unsolved patients were tackled by CMA and NGS (Fig. 1) . The overall diagnostic yield is 36.0% (41/114). An OR with a lower 95% CI > 1 (vertical dash line) was considered a positive likehood of molecular diagnosis being associated to a given factor (shown in black bold lines). **P<0.01. Abbreviation: HtSDS, standard deviation score of height; SGA, small for gestational age; DD/ID, developmental delay/intellectual disability; GHD, growth hormone deficiency; IGF1, insulin like growth factor 1; BA, bone age; MRI, magnetic resonance imaging.
By calculating the diagnostic rate of different HtSDS ranges, patients with HtSDS between -4 and -5 and below -6 had a higher diagnostic rate than the overall yield (50.0% and 44.4%, respectively versus 36.0%), which suggests that individuals with more severe short stature tend to have a higher likelihood of finding a genetic cause. However, there had been no difference between each HtSDS group ( Fig.  2A, 
.963, P=0.327). The diagnostic rates vary in different additional phenotype subgroups. Each additional phenotype subgroup could be further divided into two groups: the additional phenotype being only one accompanying phenotype or one of accompanying phenotypes. However, there were no statistical significant differences amongst groups (all P > 0.05, Supplementary Table 4) .
As the definition of idiopathic short stature is vague, different clinician might catalog patient differs with each other. To avoid such ambiguity, we examined the cohort retrospectively following Dauber's algorithm (Fig. 3 , modified from Dauber 2014, JCEM) [9] . 33 patients could be classified as idiopathic short stature (Supplementary Table 1 ). In this group, genetic background was identified in seven patients. The yield is 21.2% (7/33).
Comparison with the standard diagnostic algorithm
Dauber et al. [9] proposed a diagnostic algorithm to search for the genetic background of short stature (Fig. 3 , modified from Dauber 2014, JCEM). This diagnostic algorithm counts on clinician's experience greatly, such as the first step "Does the patient have a distinct recognizable genetic syndrome?" Different clinicians might recognize different patients so that the patient might have went through totally different diagnose pathways depending on the specialist he visited. To minimize the effect caused by experience, we examined the 114 cases retrospectively entirely based on the molecular diagnosis result. The 41 diagnosed patients were allocated to the algorithm based on the clinical manifestation. 19 out of the Cellular Physiology and Biochemistry
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41 diagnosed patients could be tackled before the last high throughput method (Marked in Fig. 3 ). Five of the 19 patients would be diagnosed in the first step as they show distinct recognizable features. Majority (13/19) would be diagnosed for the skeletal anomaly, including four patients with FGFR3 defects. 95 (83.3%) patients would be studied by NGS/ CMA in the last step eventually. Take into the consideration the heterogeneity of clinical features and possible false negative results of various tests, the number of patients that falls into the last step would be greater.
Discussion
Herein, we present genetic findings from 114 Chinese children with previously unexplained short stature. We identified causes in 41 patients through NGS and CMA, attaining a positive rate of 36.0%, which was comparable to that previously reported in a similar study (5/14, 35.7%) [21] , and higher than that provided by WES in a large cohort of patients with suspected genetic conditions (504/2000, 25.2%) [22] . Our study confirmed the utility of high-throughput molecular detection techniques in the diagnosis of short stature with unknown etiology. In this study, more than 90% of solved patients were diagnosed by Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry NGS, suggesting that NGS would be a preferred option for genetic evaluation of undiagnosed short stature. It is proposed based on experience that the severity of short stature, SGA without catch up growth, presence of one or more additional clinical/biochemical abnormalities, presence of sibling or parent with similar features may indicate a genetic cause of short stature [9, 18] . To validate the notion, we adopted statistical analysis to test these factors in our cohort. Although we observed the diagnostic yields varied in different groups of short stature severity, with or without a given additional phenotype, and presence of one or more additional phenotypes, none was statistically different except for facial dysmorphism and skeletal abnormalities (Fig. 2B) . That is, patients with short stature who has additional features including facial dysmorphism or skeletal abnormalities might have a potential genetic etiology. Therefore, we provided the first evidence that clinicians would be more likely to identify disease-causing variants in these subgroups. However, evidence in a larger cohort is required to confirm our conclusion. Additionally, no variant was detected in children with isolated short stature in this study (Table 1, Supplementary Table 1) . Their pathogenic variants might be located in genes or regions not present in the current panel. Alternatively, they may be constitutional delay of growth and puberty and their final adult height might be normal, thus followup is needed of these individuals.
As compared with the standard diagnostic algorithm, even in the ideal scenario, ~80% patients would be examined by the high throughput methods-NGS/CMA. In this next generation era, NGS become affordable by diagnosis. In addition, new algorithm allows to call CNVs from NGS data. Indeed, we applied XHMM to call CNVs from the 114 datasets. CNVs of P42, P75 and P109 could be detected with the exception of P83 (data now shown). The negative CNV result of P83 is probably due to the size of deletion is too small. As previously (Fig. 4) . After the growth and pertinent historical information collection, the patients were differentiated of Turner syndrome and FGFR3 related disorders. The rest of the patients will be evaluated by panel/exome sequencing. The candidate mutation would guide the clinical evaluations such as the endocrine test, skeletal survey and other relevant test. The results would help to confirm the NGS data and target the genetic etiology. For the negative cases, if the NGS data suggest CNVs related to short stature, a chromosomal microarray would be ordered. Based on the phenotypes, the rest cases would be tested for Silver-Russell syndrome. This algorithm takes into consideration the techniques that would be used and simplify the standard one by moving the panel/exome sequencing forward. Nevertheless, NGS/CMA would not solve every case. The negative cases need further investigation.
In conclusion, our study confirmed the utility of high-throughput molecular detection techniques in diagnosis of short stature. 41 of 114 Chinese children with undiagnosed short stature were tackled by NGS and CMA. The diagnostic yield reaches 36.0% including 46 different variants in 29 genes and two pathogenic CNVs. Patients with facial dysmorphism and/or skeletal abnormalities had a significantly higher diagnostic rate than those without the corresponding phenotype, which suggested these two phenotypes might be applied as predictors for etiology of short stature by genetic testing, but more samples are required to further validate these findings. By comparison with the standard diagnostic algorithm, 83.3% patients would be evaluated by NGS/CMA. We proposed a simplified algorithm by moving NGS forward. Hopefully in the next generation era, it would help to improve the yield of the molecular diagnosis of short stature.
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